ICAD.Icad INC

DEFM14A: RadNet to Acquire iCAD in All-Stock Merger Deal Valued at $105 Million

Sentiment:

Merger Announcement

📋All filings for Icad INC
🔒Login to Follow

RadNet, Inc. and iCAD, Inc. have entered into a definitive agreement for RadNet to acquire iCAD in an all-stock merger transaction.

Summary

  • iCAD, Inc. is set to be acquired by RadNet, Inc. through a merger agreement dated April 15, 2025.
  • The merger will see Trio Merger Sub, Inc., a wholly-owned subsidiary of RadNet, merge into iCAD, with iCAD surviving as a wholly-owned subsidiary of RadNet.
  • iCAD stockholders will receive 0.0677 shares of RadNet Common Stock for each share of iCAD Common Stock they own.
  • This exchange ratio is fixed and will not be adjusted for market price fluctuations.
  • Based on RadNet's closing price on April 14, 2025, the exchange ratio represents an implied value of approximately $3.61 per iCAD share; based on the closing price on May 20, 2025, the implied value is approximately $4.07 per iCAD share.
  • The transaction is subject to iCAD stockholder approval and customary regulatory approvals.
  • The iCAD Board has unanimously approved the merger and recommends that iCAD stockholders vote in favor of the merger agreement.
  • The special meeting for iCAD stockholders to vote on the merger is scheduled for July 14, 2025.
  • Following the merger, iCAD Common Stock will be delisted from The Nasdaq Capital Market.
  • RadNet estimates it will issue approximately 2,024,584 shares of RadNet Common Stock pursuant to the Merger Agreement.
  • Following completion of the Merger, holders of RadNet Common Stock as of immediately prior to the Merger will hold approximately 97.4% and holders of iCAD Common Stock as of immediately prior to the Merger will hold approximately 2.6% of the outstanding shares of RadNet Common Stock on a fully diluted basis.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining the benefits of the merger and the unanimous recommendation of the iCAD Board. However, it also acknowledges potential risks and uncertainties.

Positives

  • iCAD stockholders will receive shares in a larger, more liquid company.
  • The merger is intended to be a tax-free reorganization for U.S. federal income tax purposes.
  • The iCAD Board believes the merger is in the best interests of iCAD and its stockholders.
  • The exchange ratio represents an approximately 98% premium to iCAD stockholders based on iCADs closing stock price on Monday, April 14, 2025, the trading day immediately prior to the announcement of the Merger Agreement.

Negatives

  • iCAD stockholders will no longer have an equity interest in iCAD.
  • The value of RadNet Common Stock may fluctuate, affecting the ultimate value received by iCAD stockholders.
  • iCAD stockholders will have a significantly lower ownership and voting interest in RadNet than they currently have in iCAD and will exercise less influence over management.

Risks

  • The fixed exchange ratio means the value of the merger consideration is subject to RadNet's stock price fluctuations.
  • Integration of the two companies may be challenging and may not result in the anticipated benefits.
  • Key iCAD employees may be difficult to retain.
  • The merger is subject to conditions and may not be completed.
  • iCAD stockholders are not entitled to appraisal rights in connection with the Merger.

Future Outlook

RadNet and iCAD expect to complete the Merger in the second or third quarter of 2025, subject to the satisfaction of closing conditions.

Management Comments

  • The iCAD Board has determined that the Merger Agreement and the consummation of the transactions contemplated thereby, (including the Merger), are advisable and fair to, and in the best interests of, iCAD and the stockholders of iCAD.

Industry Context

The merger reflects a trend of consolidation in the medical imaging and AI-powered cancer detection industries, as companies seek to expand their product offerings and market reach.

Comparison to Industry Standards

  • Piper Sandler performed a selected public companies analysis, comparing iCAD to other unprofitable growth medical technology companies such as AtriCure, Inc., Neuronetics, Inc., and Pulmonx Corporation.
  • The analysis considered EV/Revenue and EV/Gross Profit multiples.
  • Piper Sandler also performed a selected M&A transactions analysis, reviewing deals involving unprofitable growth medical technology companies such as Paragon 28, Inc. and Silk Road Medical, Inc.
  • The analysis considered EV/Revenue and EV/Gross Profit multiples in these transactions.
  • Piper Sandler also reviewed M&A transactions announced since January 1, 2014 involving those public and private target businesses for which Piper Sandler had access to sufficient financial information and that Piper Sandler considered to be in the medical technology industry with (i) LTM revenue less than or equal to $500 million, (ii) projected FTM revenue growth between 5% and 20%, (iii) LTM gross margin greater than or equal to 65%.

Stakeholder Impact

  • iCAD stockholders will receive RadNet Common Stock and will become stockholders of RadNet.
  • iCAD employees may experience uncertainty about their future roles.
  • RadNet stockholders will own shares in a larger consolidated company.

Next Steps

  • iCAD stockholders will vote on the merger agreement at a special meeting on July 14, 2025.
  • RadNet and iCAD will seek regulatory approvals.
  • RadNet will work to list the shares of RadNet Common Stock to be issued in the Merger on The Nasdaq Global Market.

Key Dates

DateDescription
April 17, 2023iCAD and RadNet had a conference call to discuss a potential strategic transaction.
April 19, 2023iCAD and RadNet executed a mutual nondisclosure agreement.
October 2023iCAD sold substantially all of the assets and liabilities primarily related to its Xoft business.
October 2024iCAD Board formed a strategic committee to evaluate strategic alternatives.
December 2, 2024Ms. Brown, Dr. Berger and Dr. Sorensen met in person at the Radiological Society of North America annual meeting to discuss if iCAD was open to a merger transaction.
December 13, 2024RadNet sent a proposed non-binding letter of intent and a proposed exclusivity letter agreement to iCAD.
December 18, 2024iCAD received a non-binding proposal from the Private Party outlining a potential 10% minority investment in iCAD and an option to purchase up to another 10% of iCAD Common Stock.
December 19, 2024A special meeting of the iCAD Board was held with representatives of Dentons in attendance.
December 27, 2024iCAD and Piper Sandler finalized an engagement letter to effect the engagement of Piper Sandler as iCADs financial advisor.
January 6, 2025Representatives of iCAD, RadNet and Piper Sandler held an in-person meeting at Piper Sandlers offices in Boston.
January 17, 2025The iCAD Board held a regularly scheduled meeting with representatives of Dentons and Piper Sandler in attendance.
January 20, 2025Dr. Sorensen and Ms. Brown discussed the valuation via telephone, during which Dr. Sorensen communicated that RadNet would be willing to move forward with the proposed stock-for-stock transaction at an implied iCAD equity value of $96 million.
January 23, 2025A special meeting of the Strategic Committee was held.
January 27, 2025Mr. Sassine and Ms. Brown participated in a video conference meeting with Dr. Berger and Dr. Sorensen regarding the proposed implied valuation of iCAD.
January 29, 2025RadNet submitted an updated non-binding letter of interest to acquire 100% of iCADs equity for a total purchase price of $105 million.
January 30, 2025The Strategic Committee met telephonically with representatives of Piper Sandler and Dentons to discuss the updated proposal.
January 31, 2025A continuation of the January 17, 2025, iCAD Board meeting was held with representatives of Dentons in attendance.
February 3, 2025RadNet submitted an updated non-binding letter of interest to acquire 100% of iCADs equity based on an aggregate implied equity value of $105 million, which would be reduced by an amount equal to 50% of iCADs incurred transaction expenses.
February 3, 2025Following receipt of the RadNet updated February 3, 2025 proposed letter of interest, the Strategic Committee met later that day with representatives of Piper Sandler and Dentons to discuss the terms of the proposal.
February 4, 2025Ms. Brown e-mailed Dr. Sorensen a revised proposal.
February 7, 2025RadNet submitted a further revised non-binding letter of interest, which reflected the terms of the prior February 5, 2025 revised non-binding letter of interest proposed by iCAD, including a $105 million implied equity value for iCAD.
February 7, 2025Following receipt of the RadNet updated proposed letter of interest, the Strategic Committee met with representatives of Piper Sandler and Dentons later that same day to discuss the terms of the updated proposal.
February 8, 2025the iCAD Board, following a recommendation from the Strategic Committee, executed a unanimous written consent authorizing Ms. Brown to execute the non-binding letter of interest and the exclusivity letter.
February 9, 2025Dr. Sorensen delivered a countersigned copy to Ms. Brown of the non-binding letter of interest and the exclusivity letter.
February 10, 2025Dr. Sorensen sent Ms. Brown a preliminary due diligence request list, which was updated on February 12, 2025.
February 10, 2025 February 16, 2025representatives of iCAD, RadNet and Piper Sandler held a number of telephonic and Zoom meetings to discuss the preparation and organization of a virtual data room containing due diligence information and the process for furnishing access to such data room to RadNet and Perkins Coie.
February 11, 2025representatives of Perkins Coie delivered a request for legal due diligence materials to Piper Sandler, via representatives of RadNet.
February 13, 2025RadNet and its legal and accounting advisors were provided access to the virtual data room.
February 17, 2025representatives of iCAD, RadNet and their advisors took part in a call to discuss the status of the virtual data room, the diligence tracker being used to confirm that all diligence was being provided or addressed and next steps in the process.
February 21, 2025representatives of Dentons and Perkins Coie held an introductory call to discuss the general timeline of the transaction and certain high-level deal questions addressed in part in the non-binding letter of interest delivered on February 7, 2025.
February 2025 March 2025RadNet and its advisors and representatives conducted due diligence with the assistance of members of iCAD management and representatives of Piper Sandler and Dentons, which included multiple due diligence meetings and responses to several additional due diligence requests.
March 8, 2025representatives of Perkins Coie delivered an initial draft of the merger agreement to representatives of Dentons.
March 10, 2025representatives of Dentons, Piper Sandler and the Strategic Committee discussed the draft merger agreement and agreed to propose a limited number of changes.
March 12, 2025Dentons shared a proposed revised draft of the merger agreement with the Strategic Committee.
March 14, 2025representatives of Dentons held a call with iCAD to discuss the shared markup of the draft merger agreement that it intended to deliver to Perkins Coie.
March 17, 2025representatives of Dentons held a call with iCAD to discuss the preparation of the disclosure letter relating to the draft merger agreement.
March 18, 2025 March 25, 2025representatives of iCAD, RadNet, Dentons and Perkins Coie held various calls to discuss certain intellectual property, data privacy and healthcare regulatory matters related to the proposed transaction and continued to attend to other supplementary due diligence requests and questions received.
March 27, 2025representatives of Perkins Coie delivered to representatives of Dentons a revised draft of the merger agreement.
March 31, 2025representatives of Dentons and Perkins Coie held a call to discuss certain open issues in the Merger Agreement.
April 1, 2025representatives of Dentons delivered to representatives of Perkins Coie a revised draft of the merger agreement, which again proposed to calculate the floating exchange ratio using the treasury stock method.
April 1, 2025representatives of Dentons delivered to representatives of Perkins Coie an initial draft of the iCAD disclosure letter relating to the draft merger agreement.
April 2, 2025Piper Sandler delivered a customary relationship disclosure letter regarding its lack of relationship with RadNet to representatives of iCAD and Dentons.
April 4, 2025representatives of RadNet discussed with representatives of iCAD updates to the potential timeline for the execution and announcement of the transaction.
April 4, 2025 April 7, 2025representatives of Piper Sandler and, iCAD and RadNet engaged in a number of discussions regarding the proposed transaction and their views as to iCADs implied equity value in any stock-for-stock merger transaction.
April 7, 2025Dr. Sorensen, along with Kees Wesdorp, Chief Executive Officer of DeepHealth, held a videoconference with Ms. Brown and a representative of Piper Sandler to discuss the potential transaction.
April 7, 2025 April 11, 2025Following discussions among representatives of RadNet, iCAD, the Strategic Committee and Piper Sandler over the course of April 7, 2025 to April 11, 2025, RadNet confirmed on April 9, 2025, a revised proposal at an implied equity value of $105 million based on a fixed exchange ratio determined using the closing price of RadNets common stock as of April 9, 2025.
April 9, 2025representatives of Perkins Coie delivered to representatives of Dentons a revised draft of the merger agreement, which included the fixed exchange ratio previously discussed, but contemplated that this exchange ratio would be determined based on the fully-diluted capital stock of iCAD, rather than the treasury stock method.
April 10, 2025representatives of Dentons delivered to representatives of Perkins Coie a further revised draft of the merger agreement.
April 10, 2025representatives of Perkins Coie delivered to representatives of Dentons an exclusivity extension letter, which would amend the expiration of the exclusivity period under the existing exclusivity letter to expire on April 16, 2025.
April 10, 2025a special meeting of the Strategic Committee was held.
April 11, 2025the exclusivity extension letter was executed by iCAD and RadNet.
April 11, 2025a representative of Piper Sandler and Dr. Berger engaged in a conversion regarding the methodology for calculating the exchange ratio and how in-the-money options and out-of-the money options would be treated for purposes of calculating the exchange ratio.
April 11, 2025a special meeting was held with the iCAD Board and representatives of Dentons and Piper Sandler.
April 11, 2025 April 12, 2025representatives of Perkins Coie and representatives of Dentons shared several drafts of (i) the form of voting and support agreement to be executed by iCAD directors concurrently with the execution of the merger agreement, (ii) the disclosure schedules accompanying the merger agreement, (iii) a joint press release announcing the execution of the merger agreement, (iv) each of the parties current reports on Form 8-K and (v) draft communications materials.
April 12, 2025representatives of Perkins Coie shared with representatives of Dentons a further revised draft of the merger agreement.
April 12, 2025representatives of Dentons shared with representatives of Perkins Coie a further revised draft of the merger agreement, which, among other things, provided for (i) a one-year exercise period for the eligible iCAD options that were non-qualified stock options, subject to certain exceptions and limitations, and (ii) subject to the terms and conditions under the severance guidelines referenced in the merger agreement and set forth in the confidential disclosure schedules thereto, preservation of such severance guidelines for any eligible continuing U.S. employee that experienced a qualifying termination of employment within 60 days following the closing of the proposed transaction.
April 12, 2025representatives of Perkins Coie delivered a further revised draft of the merger agreement, which eliminated the one-year exercise period for the eligible iCAD options and preservation of the severance guidelines as outlined above.
April 13, 2025 April 14, 2025representatives of Perkins Coie and Dentons continued to trade drafts of the disclosure schedules, voting and support agreement, press release, Form 8-Ks, communications materials and other transaction documents.
April 14, 2025Dr. Sorensen and Ms. Brown engaged in a conversation with respect to all remaining open issues.
April 14, 2025representatives of Perkins Coie shared with representatives of Dentons updates to the potential timeline for the execution and announcement of the transaction and conference calls with RadNet and iCAD stockholders.
April 14, 2025representatives of Dentons delivered a further revised draft of the merger agreement, which contemplated (i) a one-year exercise period for the eligible iCAD options that were non-qualified stock options, subject to certain exceptions and limitations, and (ii) subject to the terms and conditions under the severance guidelines referenced in the merger agreement and set forth in the confidential disclosure schedules thereto, preservation of such severance guidelines for any eligible continuing U.S. employee that experienced a qualifying termination of employment within 60 days following the closing of the proposed transaction.
April 15, 2025representatives of Perkins Coie confirmed that the revised draft delivered by Dentons on the previous day was materially complete and final.
April 15, 2025the iCAD Board held a special meeting, with representatives from Dentons and Piper Sandler in attendance, to consider the proposed transaction.
April 15, 2025the iCAD Board unanimously (i) approved and declared advisable the Merger Agreement and the transactions contemplated therein, including the Merger, on the terms and subject to the conditions set forth therein, (ii) determined that the Merger Agreement and the consummation of the transactions contemplated thereby, (including the Merger), are advisable and fair to, and in the best interests of, iCAD and the stockholders of iCAD, (iii) resolved to recommend the adoption of the Merger Agreement to the stockholders of iCAD, on the terms and subject to the conditions set forth therein, and (iv) directed that the Merger Agreement be submitted to the stockholders of iCAD for adoption at the Special Meeting.
April 15, 2025representatives of Piper Sandler then reviewed and discussed Piper Sandlers financial analyses relating to the proposed transaction.
April 15, 2025representatives of Piper Sandler rendered an oral opinion of Piper Sandler to the iCAD Board (which was subsequently confirmed in writing by delivery of Piper Sandlers written opinion addressed to the iCAD Board dated April 15, 2025), to the effect that, as of such date and based on and subject to the assumptions made, procedures followed, matters considered and limitations on the scope of the review undertaken by Piper Sandler, as described in its written opinion, the Exchange Ratio was fair, from a financial point of view, to the holders of iCAD Common Stock who would receive RadNet Common Stock in the Merger.
April 15, 2025the Merger Agreement was executed by iCAD and RadNet.
April 15, 2025Following the closing of trading on the U.S. public stock markets, RadNet and iCAD issued a joint press release announcing the execution of the Merger Agreement.
April 17, 2025iCAD and RadNet amended the Non-Disclosure Agreement to extend the term to April 19, 2026.
April 14, 2025closing price per share of RadNet Common Stock was $ 53.36
April 14, 2025closing price per share of iCAD Common Stock was $ 1.82
May 20, 2025closing price per share of RadNet Common Stock was $ 60.16
May 20, 2025closing price per share of iCAD Common Stock was $ 3.96
May 16, 2025the iCAD Board approved the iCAD Option Extension Amendments relating to an aggregate of 1,828,124 iCAD Options that each have an exercise price per share of iCAD Common Stock that is less than $7.20, which included an aggregate of 1,478,124 iCAD Options held by iCAD directors and executive officers.
July 14, 2025The Special Meeting will be a virtual only meeting conducted exclusively via live webcast at www.cstproxy.com/icad/sm2025 starting at 9:00 a.m., Eastern Time (with log-in beginning at 8:45 a.m. Eastern Time).
Second or third quarter of 2025RadNet and iCAD currently expect to complete the Merger.
September 30, 2025Outside Date for the Merger.
December 31, 2025Extended Outside Date for the Merger if certain conditions are met.

Keywords

merger, acquisition, iCAD, RadNet, stockholders, agreement, Common Stock, Exchange Ratio, subsidiary, approval

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.